<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02998541</url>
  </required_header>
  <id_info>
    <org_study_id>SHP640-301</org_study_id>
    <secondary_id>2016-002439-14</secondary_id>
    <nct_id>NCT02998541</nct_id>
  </id_info>
  <brief_title>Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo</brief_title>
  <official_title>A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine and Placebo in the Treatment of Adenoviral Conjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if an investigational treatment is effective
      compared with placebo and PVP-Iodine in the treatment of adults and children with adenoviral
      conjunctivitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2017</start_date>
  <completion_date type="Anticipated">May 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Resolution Status Between SHP640 and Placebo as Measured by Absence of Bulbar Conjunctival Injection</measure>
    <time_frame>Day 6</time_frame>
    <description>Clinical resolution of adenoviral conjunctivitis is defined as the absence (score=0) of bulbar conjunctival injection and watery conjunctival discharge in the study eye. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. Bulbar conjunctival injection will be assessed based on a 0-4 scale which uses pictures from the validated bulbar redness (VBR) scale. Watery conjunctival discharge will be assessed based on a 0-3 scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Resolution Status Between SHP640 and Placebo as Measured by Watery Conjunctival Discharge</measure>
    <time_frame>Day 6</time_frame>
    <description>Clinical resolution of adenoviral conjunctivitis is defined as the absence (score=0) of bulbar conjunctival injection and watery conjunctival discharge in the study eye. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. Bulbar conjunctival injection will be assessed based on a 0-4 scale which uses pictures from the validated bulbar redness (VBR) scale. Watery conjunctival discharge will be assessed based on a 0-3 scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Resolution Between SHP640 and Povidone-Iodine (PVP-I) as Measured by Absence of Bulbar Conjunctival Injection</measure>
    <time_frame>Day 6</time_frame>
    <description>Clinical resolution of adenoviral conjunctivitis is defined as the absence (score=0) of bulbar conjunctival injection and watery conjunctival discharge in the study eye. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. Bulbar conjunctival injection will be assessed based on a 0-4 scale which uses pictures from the validated bulbar redness (VBR) scale. Watery conjunctival discharge will be assessed based on a 0-3 scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adenoviral Eradication Between PVP-I and Placebo as Measured by Negative Cell Culture-Immunofluorescence Assay (CC-IFA)</measure>
    <time_frame>Day 3</time_frame>
    <description>Adenoviral eradication for the study eye is defined as negative CC-IFA in that eye. CCIFA for each eye will be conducted using conjunctival swab samples collected at each visit to determine the presence of adenovirus. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adenoviral Eradication Between SHP640 and Placebo as Measured by Negative Cell Culture-Immunofluorescence Assay (CC-IFA)</measure>
    <time_frame>Day 6</time_frame>
    <description>Adenoviral eradication for the study eye is defined as negative CC-IFA in that eye. CCIFA for each eye will be conducted using conjunctival swab samples collected at each visit to determine the presence of adenovirus. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adenoviral Eradication Between SHP640 and PVP-I as Measured by Negative Cell Culture-Immunofluorescence Assay (CC-IFA)</measure>
    <time_frame>Day 6</time_frame>
    <description>Adenoviral eradication for the study eye is defined as negative CC-IFA in that eye. CCIFA for each eye will be conducted using conjunctival swab samples collected at each visit to determine the presence of adenovirus. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Resolution Between PVP-I and Placebo as Measured by Absence of Bulbar Conjunctival Injection</measure>
    <time_frame>Day 6</time_frame>
    <description>Clinical resolution of adenoviral conjunctivitis is defined as the absence (score=0) of bulbar conjunctival injection and watery conjunctival discharge in the study eye. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. Bulbar conjunctival injection will be assessed based on a 0-4 scale which uses pictures from the validated bulbar redness (VBR) scale. Watery conjunctival discharge will be assessed based on a 0-3 scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adenovirus Viral Titer Assessed by Quantitative Polymerase Chain Reaction (qPCR)</measure>
    <time_frame>Day 6 and Day 8</time_frame>
    <description>qPCR test will be performed on all CC-IFA positive samples at all visits to determine viral count in the study eye. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adenoviral Eradication as Assessed by Cell Culture-Immunofluorescence Assay (CC-IFA)</measure>
    <time_frame>Day 8 and Day 12</time_frame>
    <description>Adenoviral eradication for the study eye is defined as negative CC-IFA in that eye. CCIFA for each eye will be conducted using conjunctival swab samples collected at each visit to determine the presence of adenovirus. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Resolution of Adenoviral Conjunctivitis</measure>
    <time_frame>Day 3, Day 8 and Day 12</time_frame>
    <description>Clinical resolution of adenoviral conjunctivitis is defined as the absence (score=0) of bulbar conjunctival injection and watery conjunctival discharge in the study eye. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. Bulbar conjunctival injection will be assessed based on a 0-4 scale which uses pictures from the validated bulbar redness (VBR) scale. Watery conjunctival discharge will be assessed based on a 0-3 scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Clinical Signs</measure>
    <time_frame>Day 3, Day 6, Day 8 and Day 12</time_frame>
    <description>Individual Clinical Signs for bulbar conjunctival injection and watery conjunctival discharge will be assessed in the study eye. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Clinical Score</measure>
    <time_frame>Day 3, Day 6, Day 8 and Day 12</time_frame>
    <description>Global clinical score is the sum of bulbar conjunctival injection and watery conjunctival discharge. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in The Global Clinical Score</measure>
    <time_frame>Day 3, Day 6, Day 8 and Day 12</time_frame>
    <description>Global clinical score is the sum of bulbar conjunctival injection and watery conjunctival discharge. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Clinical Resolution</measure>
    <time_frame>Day 3, Day 6, Day 8 and Day 12</time_frame>
    <description>Modified clinical resolution is defined as a global clinical score of 0 or 1 in the study eye. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Clinical Resolution</measure>
    <time_frame>Day 3, Day 6, Day 8 and Day 12</time_frame>
    <description>Expanded clinical resolution is defined as a global clinical score of 0, 1, or 2 with neither injection nor discharge having a score of 2 in the study eye. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Resolution</measure>
    <time_frame>Day 3, Day 6, Day 8 and Day 12</time_frame>
    <description>Time to clinical resolution based upon assessments will be analysed in the study eye. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status of Cross-over Infection</measure>
    <time_frame>Day 3, Day 6, Day 8 and Day 12</time_frame>
    <description>The status of cross-over infection which is assessed by CC-IFA to a subject's fellow eye will be for subjects with only 1 infected eye at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of SHP640 as compared to PVP-I and Placebo</measure>
    <time_frame>Day 1 up to Day 13</time_frame>
    <description>Safety and tolerability of SHP640, compared to PVP-I and placebo will be evaluated in the treatment of subjects with adenoviral conjunctivitis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Resolution Between SHP640 and Povidone-Iodine (PVP-I) as Measured by Watery Conjunctival Discharge</measure>
    <time_frame>Day 6</time_frame>
    <description>Clinical resolution of adenoviral conjunctivitis is defined as the absence (score=0) of bulbar conjunctival injection and watery conjunctival discharge in the study eye. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. Bulbar conjunctival injection will be assessed based on a 0-4 scale which uses pictures from the validated bulbar redness (VBR) scale. Watery conjunctival discharge will be assessed based on a 0-3 scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Resolution Between PVP-I and Placebo as Measured by Watery Conjunctival Discharge</measure>
    <time_frame>Day 6</time_frame>
    <description>Clinical resolution of adenoviral conjunctivitis is defined as the absence (score=0) of bulbar conjunctival injection and watery conjunctival discharge in the study eye. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. Bulbar conjunctival injection will be assessed based on a 0-4 scale which uses pictures from the validated bulbar redness (VBR) scale. Watery conjunctival discharge will be assessed based on a 0-3 scale.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">930</enrollment>
  <condition>Adenoviral Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>SHP640</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Instill 1 drop of SHP640 (0.1 percent [%] Dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye 4 times daily (QID) for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PVP-I 0.6%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Instill 1 drop of PVP-I ophthalmic solution in each eye QID for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHP640</intervention_name>
    <description>Instill 1 drop of SHP640 (0.1 % Dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days.</description>
    <arm_group_label>SHP640</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PVP-I 0.6%</intervention_name>
    <description>Instill 1 drop of PVP-I ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.</description>
    <arm_group_label>PVP-I 0.6%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Instill 1 drop of placebo ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects of any age at Visit 1.

          2. Have a positive AdenoPlus® test at Visit 1 in at least 1 eye.

          3. Have a clinical diagnosis of suspected adenoviral conjunctivitis in at least 1 eye
             (the same eye as the AdenoPlus positive eye) confirmed by the presence of the
             following minimal clinical signs and symptoms in that same eye.

          4. Be willing to discontinue contact lens wear for the duration of the study.

          5. Have a Best Corrected Visual Acuity (BCVA) of 0.60 logarithm of the Minimum Angle of
             Resolution (logMAR) or better in each eye as measured using an Early Treatment
             Diabetic Retinopathy Study (ETDRS) chart.

          6. Other protocol defined inclusion criteria may apply

        Exclusion Criteria:

          1. Have known or suspected intolerance or hypersensitivity to the investigational
             product, closely related compounds, or any of the stated ingredients.

          2. Prior enrollment in a FST100 or SHP640 clinical study.

          3. Subjects who are employees, or immediate family members of employees (who are directly
             related to study conduct), at the investigational site.

          4. Have a history of ocular surgical intervention within ≤ 6 months prior to Visit 1 or
             planned for the period of the study.

          5. Have a preplanned overnight hospitalization during the period of the study.

          6. Have active or history of ocular herpes.

          7. Have at enrollment or within ≤30 days of Visit 1, a clinical presentation more
             consistent with the diagnosis of non-infectious conjunctivitis (except presumed
             seasonal/perennial allergic conjunctivitis) or non-adenoviral ocular infection (eg,
             bacterial, fungal, acanthamoebal, or other parasitic).

          8. Other protocol defined exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Physician</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>+1 866 842 5335</phone>
    <email>ClinicalTransparency@Shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Eye Center</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Tolle Jr</last_name>
      <phone>480-999-5458</phone>
      <email>jerry.tolle@doctrials.com</email>
    </contact>
    <investigator>
      <last_name>Michael Depenbusch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cornea and Cataract Consultants of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Komer</last_name>
      <phone>602-258-4342</phone>
      <email>ccazresearch@aol.com</email>
    </contact>
    <investigator>
      <last_name>Jung Dao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M&amp;M Eye Institute</name>
      <address>
        <city>Prescott</city>
        <state>Arizona</state>
        <zip>86301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Cook</last_name>
      <phone>480-999-5458</phone>
      <email>sean.cook@doctrials.com</email>
    </contact>
    <investigator>
      <last_name>Steven Mortenson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schwartz Laser Eye Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie O'Brien</last_name>
      <phone>480-483-3937</phone>
      <email>katieo@schwartzlaser.com</email>
    </contact>
    <investigator>
      <last_name>Marc Bloomstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Walman Eye Center</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Moriarty</last_name>
      <phone>480-999-5458</phone>
      <email>sean.moriarty@doctrials.com</email>
    </contact>
    <investigator>
      <last_name>Gerald Walman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mark B. Kislinger, MD, Inc.</name>
      <address>
        <city>Glendora</city>
        <state>California</state>
        <zip>91741</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelby Wade</last_name>
      <phone>626-335-0535</phone>
      <email>shelby.foothilleye@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vicky Pai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inland Eye Specialists</name>
      <address>
        <city>Hemet</city>
        <state>California</state>
        <zip>92545</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norlisha Borntrager</last_name>
      <phone>951-492-4205</phone>
      <email>Norlishab@inlandeyespecialists.com</email>
    </contact>
    <investigator>
      <last_name>Robert Sorenson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lakeside Vision Center</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zarah Chhoet</last_name>
      <phone>949-733-2002</phone>
      <email>Studycoordinator@drduzmanmd.com</email>
    </contact>
    <investigator>
      <last_name>Eran Duzman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eye Physicians of Long Beach</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marisela Silva</last_name>
      <phone>562-421-2757</phone>
      <email>marisela@eplb.com</email>
    </contact>
    <investigator>
      <last_name>Wayne Freeman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sok H. Nam, M.D. Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Kim</last_name>
      <phone>213-368-0388</phone>
      <email>rebecca@nameyecenter.com</email>
    </contact>
    <investigator>
      <last_name>Sok Nam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Macy Eye Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Kaesemeyer</last_name>
      <phone>310-657-2777</phone>
      <email>scott@macyeyecenter.com</email>
    </contact>
    <investigator>
      <last_name>Jonathan Macy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Byers Eye Institute. Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Nunez</last_name>
      <phone>650-497-7846</phone>
      <email>mnunez1@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Charles Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shasta Eye Medical Group, Inc.</name>
      <address>
        <city>Redding</city>
        <state>California</state>
        <zip>96001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Miller</last_name>
      <phone>530-223-2500</phone>
      <phone_ext>2104</phone_ext>
      <email>studycoordinator@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Bruce Silverstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sacramento Eye Consultants</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Phillips</last_name>
      <phone>916-649-1515</phone>
      <phone_ext>223</phone_ext>
      <email>jaimep@saceye.com</email>
    </contact>
    <investigator>
      <last_name>Samuel Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WCCT Global</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Hong</last_name>
      <phone>714-380-2329</phone>
      <email>ann.hong@wcct.com</email>
    </contact>
    <investigator>
      <last_name>Michael Sheety</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Connecticut</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Lavin</last_name>
      <phone>203-366-8000</phone>
      <email>dlavin@occeye.com</email>
    </contact>
    <investigator>
      <last_name>James Thimons</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Windham Eye Group</name>
      <address>
        <city>Willimantic</city>
        <state>Connecticut</state>
        <zip>06226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Ferro</last_name>
      <phone>860-423-1619</phone>
      <email>weg_heather@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Michael Cooper, OD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Eye Associates of Manatee, LLP</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Stidham</last_name>
      <phone>941-792-2020</phone>
      <phone_ext>2649</phone_ext>
      <email>rstidham@theeyeassociates.com</email>
    </contact>
    <investigator>
      <last_name>Scott Han</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Florida Vision</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Musser</last_name>
      <phone>954-977-0192</phone>
      <email>smusser@2020eyecareplan.com</email>
    </contact>
    <investigator>
      <last_name>Sunir Joshi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Millenium Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daylen Diaz</last_name>
      <phone>305-649-7999</phone>
      <email>ddiaz@millenniumresearchfl.com</email>
    </contact>
    <investigator>
      <last_name>Jorge Alvarez-Moreno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pediatric &amp; Adult Research Center, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shari Tillman</last_name>
      <phone>407-271-4208</phone>
      <email>stillman@parc-clinicaltrials.com</email>
    </contact>
    <investigator>
      <last_name>Maricor Grio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Score Physician Alliance, LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey A. Hirschfield</last_name>
      <phone>727-344-7509</phone>
      <email>md@scorephysicianalliance.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Hirschfield</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Florida Eye Institute</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34494</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kacy Brown</last_name>
      <phone>772-287-9000</phone>
      <email>klitchfield@efei.com</email>
    </contact>
    <investigator>
      <last_name>Ronald Frenkel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Logan Ophthalmic Research, LLC</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine McCall</last_name>
      <phone>954-724-5100</phone>
      <email>cmccall.LOR@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Andrew Logan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois Eye Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Therese Buie</last_name>
      <phone>309-213-0664</phone>
      <email>tbuie@illinoiseyecenter.com</email>
    </contact>
    <investigator>
      <last_name>Steve Lichtenstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MediSphere Medical Research Center, LLC</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Dela LLana</last_name>
      <phone>812-471-4110</phone>
      <email>ccovert@medisphereresearch.com</email>
    </contact>
    <investigator>
      <last_name>Alexander Dela LLana</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kannarr Eye Care</name>
      <address>
        <city>Pittsburg</city>
        <state>Kansas</state>
        <zip>66762</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Compton</last_name>
      <phone>620-235-1737</phone>
      <email>mcompton@kannarreyecare.com</email>
    </contact>
    <investigator>
      <last_name>Shane Kannarr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Haider Eye Care</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Griffith</last_name>
      <phone>502-883-1015</phone>
      <email>acgrif11@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mohammad Haider</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lakeview Vision</name>
      <address>
        <city>Gretna</city>
        <state>Louisiana</state>
        <zip>70056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Monica</last_name>
      <phone>504-391-7560</phone>
      <email>mlong511@bellsouth.net</email>
    </contact>
    <investigator>
      <last_name>Monica Monica</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eye Associates of Northeast Louisiana dba Haik Humble Eye Center</name>
      <address>
        <city>West Monroe</city>
        <state>Louisiana</state>
        <zip>71291</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Johnson Webb</last_name>
      <phone>318-325-2610</phone>
      <phone_ext>326</phone_ext>
      <email>rajohnson@eyenela.com</email>
    </contact>
    <investigator>
      <last_name>Jonathan Scogin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eye Center Northeast</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christie Theriault</last_name>
      <phone>207-990-4388</phone>
      <email>Christie@eyecenternotheast.com</email>
    </contact>
    <investigator>
      <last_name>David Douglas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NECCR PrimaCare Research, LLC</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02721</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Francoeur</last_name>
      <phone>508-672-7450</phone>
      <phone_ext>21</phone_ext>
      <email>lfrancoeur@neccr.com</email>
    </contact>
    <investigator>
      <last_name>Ehab Sorial</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shire Call Center</name>
      <address>
        <city>Lexington</city>
        <state>Massachusetts</state>
        <zip>02421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shire Contact</last_name>
      <phone>866-842-5335</phone>
      <email>ClinicalTransparency@shire.com</email>
    </contact>
    <investigator>
      <last_name>Shire Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Eye Consultants, P.A.</name>
      <address>
        <city>Bloomington</city>
        <state>Minnesota</state>
        <zip>55431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Vitali</last_name>
      <phone>952-567-6070</phone>
      <email>dnvitali@mneye.com</email>
    </contact>
    <investigator>
      <last_name>Ahmad Fahmy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lifelong Vision Foundation</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Stolze</last_name>
      <phone>636-534-5126</phone>
      <email>lstolze@lifelongvisionfoundation.org</email>
    </contact>
    <investigator>
      <last_name>Mujtaba Qazi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NV Eye Physicians</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kris Taylor</last_name>
      <phone>702-588-1076</phone>
    </contact>
    <investigator>
      <last_name>Douglas Lorenz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emil A. Stein, M.D., Ltd.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emil Stein</last_name>
      <phone>973-937-8839</phone>
      <email>nevadaeyecare@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Emil Stein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Schwartz</last_name>
      <phone>856-753-7335</phone>
      <phone_ext>310</phone_ext>
      <email>kschwartz@hritrials.com</email>
    </contact>
    <investigator>
      <last_name>Michael Hassman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern New Jersey Eye Institute</name>
      <address>
        <city>South Orange</city>
        <state>New Jersey</state>
        <zip>07079</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley Vitale</last_name>
      <phone>973-763-2203</phone>
      <email>svitale@nnjei.com</email>
    </contact>
    <investigator>
      <last_name>Charles Crane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Farkas, Kassalow, Resnick &amp;Associates</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Rosin</last_name>
      <phone>212-355-5145</phone>
      <email>eyedockev@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Kevin Rosin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oculus Research at Garner EyeCareCenter</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Aune</last_name>
      <phone>713-816-3185</phone>
      <email>carol.aune.oculusresearch@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Carol Aune</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Clear Vision Institute</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Wallace</last_name>
      <phone>541-762-2763</phone>
      <email>jwallace@oregonretina.org</email>
    </contact>
    <investigator>
      <last_name>Bala Ambati</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Eye Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacki Fisher</last_name>
      <phone>412-383-9033</phone>
      <email>fisherjm2@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Deepinder Dhaliwal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wyomissing Optometric Center</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Krammes</last_name>
      <phone>610-374-3134</phone>
      <email>hkrammes@wyoopto.com</email>
    </contact>
    <investigator>
      <last_name>Glenn Corbin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bluestein Custom Vision</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Traxler</last_name>
      <phone>843-769-6655</phone>
      <email>bluesteinjill@aol.com</email>
    </contact>
    <investigator>
      <last_name>Ettahleah Bluestein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eye Specialty Group</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Sanford</last_name>
      <phone>901-685-2200</phone>
      <phone_ext>683</phone_ext>
      <email>michaelsanford@esg.md</email>
    </contact>
    <investigator>
      <last_name>Henry McQuirter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nashville Vision Associates</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandi Wilson</last_name>
      <phone>615-915-5086</phone>
      <email>brandiw@nashvillevision.com</email>
    </contact>
    <investigator>
      <last_name>Gary Jerkins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DCT- Shah Research, LLC dba Discovery Clinical Trials</name>
      <address>
        <city>Mission</city>
        <state>Texas</state>
        <zip>78572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Gomez</last_name>
      <phone>956-205-0492</phone>
      <email>mgomez@discoverytrials.com</email>
    </contact>
    <investigator>
      <last_name>Pankajkumar Shah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lone Star Eye Care, P.A.</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Cruz</last_name>
      <phone>832-606-7778</phone>
      <email>toniomd@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Matthew McMenemy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emerson Clinical Research Institute</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Zerpa</last_name>
      <phone>202-239-0777</phone>
      <phone_ext>102</phone_ext>
      <email>olga@ecrinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Gustavos Corrales</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Smith</last_name>
      <phone>608-263-7169</phone>
      <email>cmsmith37@wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Sarah Nehls</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of the Sunshine Coast Clinical Trials Centre</name>
      <address>
        <city>Sippy Downs</city>
        <state>Queensland</state>
        <zip>4556</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leo Hartley</last_name>
      <phone>(07) 5353 5080</phone>
      <email>leohartley@h2visioncentres.com.au</email>
    </contact>
    <investigator>
      <last_name>Leo Hartley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augenklinik, Studienzentrum, Kepler-Universitätsklinikum GmbH</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Ring</last_name>
      <phone>+43 05 7680 83 1944</phone>
      <email>michael.ring@kepleruniklinikum.at</email>
    </contact>
    <investigator>
      <last_name>Matthais Bolz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vienna Institute for Research in Ocular Surgery</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Pilwachs</last_name>
      <phone>+4319102157564</phone>
      <email>c.pilwachs@viros.at</email>
    </contact>
    <investigator>
      <last_name>Martin Kronschlaeger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Waterloo</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2L 3G1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Johnson</last_name>
      <phone>(519) 888-4567</phone>
      <phone_ext>35818</phone_ext>
      <email>jane.johnson@uwaterloo.ca</email>
    </contact>
    <investigator>
      <last_name>Lyndon Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Oftalmológica del Caribe S.A.S</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luis Jose Escaf</last_name>
      <phone>57 5 3363700</phone>
      <phone_ext>139</phone_ext>
    </contact>
    <investigator>
      <last_name>Luis Jose Escaf</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundación Oftalmológica Nacional - FUNDONAL</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandra Belalcazar Rey</last_name>
      <phone>57 1 3163481</phone>
      <phone_ext>1631</phone_ext>
    </contact>
    <investigator>
      <last_name>Sandra Belalcazar Rey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica de Oftalmología de Cali S.A</name>
      <address>
        <city>Cali</city>
        <zip>8C - 94</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria del Pilar Echeverri Murgueitio</last_name>
      <phone>57 2 5520890</phone>
      <phone_ext>105</phone_ext>
    </contact>
    <investigator>
      <last_name>Maria del Pilar Echeverri Murgueitio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Médico Imbanaco de Cali S.A</name>
      <address>
        <city>Cali</city>
        <zip>B 2-04</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Martinez Blanco</last_name>
      <phone>57 2 6821000</phone>
      <phone_ext>14091</phone_ext>
    </contact>
    <investigator>
      <last_name>Alexander Martinez Blanco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Investigación en Oftalmología Ltda.</name>
      <address>
        <city>Medellín</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Patricia Acosta Cadavid</last_name>
      <phone>57 4 2355888</phone>
    </contact>
    <investigator>
      <last_name>Claudia Patricia Acosta Cadavid</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eye Clinic Dr Kirsta Turman (Kreutzwaldi Silmakeskus)</name>
      <address>
        <city>Tallinn</city>
        <zip>10120</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Utsar</last_name>
      <phone>+372 5152 887</phone>
      <email>ritautsar@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Krista Turman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Tallinn Central Hospital Eye Clinic</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kadi Palumaa</last_name>
      <phone>+3725200602</phone>
      <email>kadi.palumaa@itk.ee</email>
    </contact>
    <investigator>
      <last_name>Kadi Palumaa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tartu University Eye Clinic</name>
      <address>
        <city>Tartu</city>
        <zip>51010</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maris Oll</last_name>
      <phone>+3725092657</phone>
      <email>maris.oll@kliinikum.ee</email>
    </contact>
    <investigator>
      <last_name>Maris Oll</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SZTE Szemeszeti Klinika</name>
      <address>
        <city>Szeged</city>
        <state>Csongrad</state>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hadarits Flora</last_name>
      <phone>003630 205 6163</phone>
    </contact>
    <investigator>
      <last_name>Andrea Facskó</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bugat Pal Hospital Clinexpert Gyongyos</name>
      <address>
        <city>Gyongyos</city>
        <state>Heves</state>
        <zip>3200</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabor Erdei</last_name>
      <phone>+36 30 983 0641</phone>
      <email>coordination.clinexpert@bugatpal.hu</email>
    </contact>
    <investigator>
      <last_name>Ilona Elek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaposi Mór Hospital</name>
      <address>
        <city>Kaposvár</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Balázs Kovács</last_name>
      <phone>+36 70 312 6040</phone>
      <email>kovacsb.eyemed@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Balázs Kovács</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sharey Zedek MC</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katz Yael</last_name>
      <phone>+972-2-6666002</phone>
      <email>yaelkatz@szmc.org.il</email>
    </contact>
    <investigator>
      <last_name>David Zadok</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Medicel Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Merav Yehuda</last_name>
      <phone>+972-3-6973912</phone>
      <email>meravy@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>David Varssano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Uno-Med</name>
      <address>
        <city>Krakow</city>
        <state>Malopolska</state>
        <zip>31-070</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michal Wykrota</last_name>
      <phone>605030131</phone>
      <email>michal.wykrota.pl@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Piotr Oleksy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Diagnostyki i Mikrochirurgii Oka LENS</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-424</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaudia Kobak</last_name>
      <phone>+48 691463680</phone>
      <email>kobak.lens@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dominik Zalewski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Uno-Med</name>
      <address>
        <city>Tarnów</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Izabella Karska-Basta</last_name>
      <phone>48501533915</phone>
      <email>izabasta@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Izabella Karska-Basta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Sp. z o.o.</name>
      <address>
        <city>Warszawa</city>
        <zip>01 -364</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewa Chojnowska</last_name>
      <phone>+ 48 508 582 535</phone>
      <email>e.chojnowska@retina.pl</email>
    </contact>
    <investigator>
      <last_name>Piotr Fryczkowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newtown Clinical Research Centre</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Busie Zwane</last_name>
      <phone>+27114920336</phone>
      <email>busie@newtowncrc.co.za</email>
    </contact>
    <investigator>
      <last_name>Essack Mitha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pretoria Eye Institute</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0082</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet van Oordt</last_name>
      <phone>+2712 343 2425</phone>
      <email>janetvo@eyeinstitute.co.za</email>
    </contact>
    <investigator>
      <last_name>Petrus Nicolaas Jacobus Gous</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Into Research</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0181</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria E Booysen</last_name>
      <phone>+27 12 460 1160</phone>
      <email>booysenmaria@ymail.com</email>
    </contact>
    <investigator>
      <last_name>Heidi Siebert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Oftalmológico Fernández-Vega</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SILVIA BERISA</last_name>
      <phone>+34985240141</phone>
      <email>silvia.berisa@fernandez-vega.com</email>
    </contact>
    <investigator>
      <last_name>Jesús Merayo-Lloves</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Oftalmologia Gil Piña</name>
      <address>
        <city>Huelva</city>
        <zip>21002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maribel Perez Marquez</last_name>
      <phone>+34959261544</phone>
      <email>administracion@gilpiña.com</email>
    </contact>
    <investigator>
      <last_name>Gil Pina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Rementeria</name>
      <address>
        <city>Madrid</city>
        <zip>28010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>INES CONTRERAS</last_name>
      <phone>0034 913083838</phone>
      <email>contreras@clinicarementeria.es</email>
    </contact>
    <investigator>
      <last_name>Francisco Javier Hurtado Ceña</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cartujavision</name>
      <address>
        <city>Sevilla</city>
        <zip>41092</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesús Montero</last_name>
      <phone>(34) 954223066</phone>
    </contact>
    <investigator>
      <last_name>Jesús Montero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Estonia</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2016</study_first_submitted>
  <study_first_submitted_qc>December 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2016</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Inclusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Povidone-Iodine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

